Nanomaterial-based blood-brain-barrier (BBB) crossing strategies

Jinbing Xie; Zheyu Shen; Yasutaka Anraku; Kazunori Kataoka; Xiaoyuan Chen

doi:10.1016/j.biomaterials.2019.119491

Nanomaterial-based blood-brain-barrier (BBB) crossing strategies

Biomaterials. 2019 Dec:224:119491. doi: 10.1016/j.biomaterials.2019.119491. Epub 2019 Sep 14.

Authors

Jinbing Xie¹, Zheyu Shen², Yasutaka Anraku³, Kazunori Kataoka⁴, Xiaoyuan Chen⁵

Affiliations

¹ Jiangsu Key Laboratory of Molecular Imaging and Functional Imaging, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, 210009, China; Innovation Center of NanoMedicine, Kawasaki Institute of Industrial Promotion, 3-25-14, Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan.
² Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: zheyu.shen@nih.gov.
³ Innovation Center of NanoMedicine, Kawasaki Institute of Industrial Promotion, 3-25-14, Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan.
⁴ Innovation Center of NanoMedicine, Kawasaki Institute of Industrial Promotion, 3-25-14, Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan; Policy Alternatives Research Institute, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan. Electronic address: kataoka@ifi.u-tokyo.ac.jp.
⁵ Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: shawn.chen@nih.gov.

Abstract

Increasing attention has been paid to the diseases of central nervous system (CNS). The penetration efficiency of most CNS drugs into the brain parenchyma is rather limited due to the existence of blood-brain barrier (BBB). Thus, BBB crossing for drug delivery to CNS remains a significant challenge in the development of neurological therapeutics. Because of the advantageous properties (e.g., relatively high drug loading content, controllable drug release, excellent passive and active targeting, good stability, biodegradability, biocompatibility, and low toxicity), nanomaterials with BBB-crossability have been widely developed for the treatment of CNS diseases. This review summarizes the current understanding of the physiological structure of BBB, and provides various nanomaterial-based BBB-crossing strategies for brain delivery of theranostic agents, including intranasal delivery, temporary disruption of BBB, local delivery, cell penetrating peptide (CPP) mediated BBB-crossing, receptor mediated BBB-crossing, shuttle peptide mediated BBB-crossing, and cells mediated BBB-crossing. Clinicians, biologists, material scientists and chemists are expected to be interested in this review.

Keywords: Blood-brain barrier (BBB); Central nervous system (CNS); Drug delivery systems; Nanomaterials.

Published by Elsevier Ltd.

Publication types

Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Blood-Brain Barrier / metabolism*
Central Nervous System Diseases / pathology
Clinical Trials as Topic
Disease Models, Animal
Drug Delivery Systems
Humans
Nanostructures / chemistry*

Abstract

Publication types

MeSH terms

Grants and funding